NYXH
Nyxoah S.A.
NASDAQ · Healthcare · Medical - Instruments & Supplies · BE
$1.62
−7.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 22.7M | 10.0M | 4.5M | 4.3M | 3.1M |
| Cost of Revenue | 11.0M | 3.7M | 1.6M | 1.7M | 1.1M |
| Gross Profit | 11.6M | 6.3M | 3.0M | 2.7M | 1.9M |
| Operating Expenses | |||||
| R&D Expense | 42.0M | 42.8M | 34.3M | 27.7M | 15.9M |
| SG&A Expense | 57.0M | 46.4M | 28.5M | 20.6M | 18.9M |
| General & Admin Expense | 39.7M | 46.4M | 27.2M | 20.6M | 17.9M |
| Selling & Marketing Expense | — | — | 1.3M | — | 914.0K |
| Other Expenses | (585.0K) | 7.0K | (1.0M) | (507.0K) | (283.0K) |
| Total Operating Expenses | 98.4M | 89.3M | 61.8M | 47.8M | 34.4M |
| Cost and Expenses | 109.4M | 93.0M | 63.3M | 49.5M | 35.6M |
| Operating Income (EBIT) | (86.8M) | (82.9M) | (58.8M) | (45.1M) | (32.5M) |
| Non-Operating | |||||
| Interest Income | 1.7M | 1.8M | 2.5M | 2.6M | 372.0K |
| Interest Expense | 15.1M | 1.7M | 1.9M | 1.2M | 237.0K |
| Net Interest Income | (13.4M) | 143.0K | 599.0K | 1.4M | 135.0K |
| Other Non-Op Income/Expense | (10.2M) | (6.1M) | 2.4M | 445.0K | 2.4M |
| Non-Operating Income (excl Interest) | (4.6M) | 4.4M | (4.3M) | (662.0K) | (2.7M) |
| EBT (Pre-Tax Income) | (96.9M) | (89.1M) | (56.4M) | (44.7M) | (30.1M) |
| Income Tax Expense | 1.5M | 1.0M | 2.8M | (1.4M) | 1.2M |
| Bottom Line | |||||
| Net Income | (98.5M) | (90.1M) | (59.2M) | (43.2M) | (31.2M) |
| Earnings from Cont. Ops | (98.5M) | (90.1M) | (59.2M) | (43.2M) | (31.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (98.5M) | (90.1M) | (59.2M) | (43.2M) | (31.2M) |
| Per Share | |||||
| Basic EPS | ($2.17) | ($2.36) | ($1.81) | ($1.55) | ($1.21) |
| Diluted EPS | ($2.17) | ($2.36) | ($1.81) | ($1.55) | ($1.21) |
| Revenue Per Share | $0.40 | $0.26 | $0.14 | $0.16 | $0.12 |
| Shares | |||||
| Basic Shares Outstanding | 57.0M | 38.1M | 32.7M | 28.0M | 25.8M |
| Diluted Shares Outstanding | 57.0M | 38.1M | 32.7M | 28.0M | 25.8M |
| Profitability Metrics | |||||
| EBITDA | (77.3M) | (82.9M) | (53.8M) | (42.1M) | (27.9M) |
| D&A | 4.9M | 4.5M | 764.0K | 2.4M | 1.9M |
| EBIT | (82.2M) | (87.4M) | (54.5M) | (44.4M) | (29.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026